Trial reportEuropean archives of psychiatry and clinical neuroscience2026
Do withdrawal symptoms predict depression relapse after antidepressant cessation?
Trial report in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Amygdala Reactivity, Antidepressant Discontinuation, and Relapse.JAMA psychiatry · 2024Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discontinuing antidepressants after remission poses risks of withdrawal symptoms and relapse. This study addressed four questions: Can withdrawal symptoms be differentiated from relapse? What are their risk factors? Are withdrawal symptoms associated with relapse? Can discontinuation be optimized? 103 patients with a remitted major depressive disorder were randomized to continue or discontinue antidepressants. Withdrawal symptoms were assessed using the Discontinuation Emergent Signs and Symptoms scale (DESS). Withdrawal syndrome was defined as experiencing at least four new or worsened DESS symptoms. Associations between clinical factors and symptom count were examined using linear regressions. After the randomization phase, all patients discontinued treatment and were monitored for six months. The relationship between withdrawal symptoms, clinical factors, and relapse risk was analyzed via logistic regression and a Cox proportional hazards model. Ten symptoms were reported exclusively in the discontinuation group and may aid in distinguishing withdrawal syndrome from relapse. Withdrawal syndrome occurred in 29% (95% PI [8.3%, 72%]) of patients. Women reported more withdrawal symptoms than men (factor 1.67 (95% PI [1.06, 2.56])). None of the other predictors were associated with symptom count. Of 83 patients with outcome data, 54 (65%) remained well and 29 (35%) relapsed. Withdrawal symptoms (0.58, 95% PI [0.07, 1.16]) and early depressive symptoms (0.63, 95% PI [0.16, 1.17]) were associated with a higher relapse risk. Tapering duration was not associated with either withdrawal symptoms or relapse rate. Withdrawal symptoms were common and more frequent in women. Experiencing withdrawal symptoms may increase relapse risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.